EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates

Liliana Ascione, Lorenzo Guidi, Ajay Prakash, Dario Trapani, Patricia LoRusso, Emil Lou, Giuseppe Curigliano iD

American Society of Clinical Oncology Educational Book · 01.06.2024 · 44 (3)

DOI: 10.1200/edbk_431766 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, erschienen am 01.06.2024. Verfasst von Liliana Ascione und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Early Drug Development, IEO, European Institute of Oncology, IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Immunoconjugates, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of chemotherapeutic agents with the selectivity of targeted therapies. At present, the approval of many ADCs used in clinical practice has not always been biomarker-driven. Indeed, predicting ADCs' activity and toxicity through the demonstration of specific biomarkers is still a great unmet need, and the identification of patients who can derive significant benefit from treatment with ADCs may often be uncertain. With the lack of robust predictive biomarkers to anticipate primary, intrinsic resistance to ADCs and no consolidated biomarkers to aid in the early identification of treatment resistance (ie, acquired resistance), the determination of precise biologic mechanisms of ADC activity and safety becomes priority in the quest for better patient-centric outcomes. Of great relevance, whether the target antigen expression is a determinant of ADCs' primary activity is still to be clarified, and available data remain quite controversial. Antigen expression assessment is typically performed on tissue biopsy, hence only providing information on a specific tumor site, therefore unable to capture heterogeneous patterns of tumor antigen expression. Quantifying the expression of the target antigen across all tumor sites would help better understand tumor heterogeneity, whereas molecularly characterizing tumor-intrinsic features over time might provide information on resistance mechanisms. In addition, toxicity can represent a critical concern, since most ADCs have a safety profile that resembles that of chemotherapies, with often unique adverse events requiring special management, possibly because of the differential in pharmacokinetics between the small-molecule agent versus payload of a similar class (eg, deruxtecan conjugate–related interstitial lung disease). As such, the identification of robust predictive biomarkers of safety and activity of ADCs has the potential to improve patient selection and enrich the population of patients most likely to derive a substantial clinical benefit, especially in those disease settings where different ADCs happen to be approved in competing clinical indications, with undefined biomarkers to make precise decision making and unclear data on how to sequence ADCs. At this point, the identification of clinically actionable biomarkers in the space of ADCs remains a top research priority.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesBiomarkers, TumorNeoplasmsHumansAntineoplastic AgentsMolecular Targeted TherapyDrug Resistance, NeoplasmTreatment Outcome

Substanzen

ImmunoconjugatesBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Early Drug Development, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy.
  • Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.
  • Yale University School of Medicine, Yale Cancer Center, New Haven, CT.

ORCID-Profile: Giuseppe Curigliano

Zitieren

APA

Ascione, L., Guidi, L., Prakash, A., Trapani, D., LoRusso, P., Lou, E., & Curigliano, G. (2024). Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book, 44(3). https://doi.org/10.1200/edbk_431766

Vancouver

Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, et al. Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book. 2024;44(3). doi:10.1200/edbk_431766

BibTeX
@article{Ascione2024,
  author = {Ascione, Liliana and Guidi, Lorenzo and Prakash, Ajay and Trapani, Dario and LoRusso, Patricia and Lou, Emil and Curigliano, Giuseppe},
  title = {Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2024},
  volume = {44},
  number = {3},
  doi = {10.1200/edbk_431766}
}
Kostenlos starten →